Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Tsuji

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
RSC Advances|January 30, 2023
Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteinsTakuya Kobayakawa, Masaru Yokoyama, Kohei Tsuji, et al.
Journal of Medicinal Chemistry|January 26, 2021
Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry InhibitorsTakuya Kobayakawa, Kohei Tsuji, Kiju Konno, et al.
Journal of Virology|December 13, 2022
Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical IsolatesKaho Matsumoto, Takeo Kuwata, William D Tolbert, et al.
Iscience|November 7, 2022
Potent and biostable inhibitors of the main protease of SARS-CoV-2Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, et al.
PNAS Nexus|January 20, 2025
An orally available P1'-5-fluorinated M<sup>pro</sup> inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrierNobuyo Higashi-Kuwata, Haydar Bulut, Hironori Hayashi, et al.
Nature Communications|February 25, 2023
Identification of SARS-CoV-2 M<sup>pro</sup> inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2Nobuyo Higashi-Kuwata, Kohei Tsuji, Hironori Hayashi, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
RSC Advances|January 30, 2023
Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteinsTakuya Kobayakawa, Masaru Yokoyama, Kohei Tsuji, et al.
Journal of Medicinal Chemistry|January 26, 2021
Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry InhibitorsTakuya Kobayakawa, Kohei Tsuji, Kiju Konno, et al.
Journal of Virology|December 13, 2022
Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical IsolatesKaho Matsumoto, Takeo Kuwata, William D Tolbert, et al.
Iscience|November 7, 2022
Potent and biostable inhibitors of the main protease of SARS-CoV-2Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, et al.
PNAS Nexus|January 20, 2025
An orally available P1'-5-fluorinated M<sup>pro</sup> inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrierNobuyo Higashi-Kuwata, Haydar Bulut, Hironori Hayashi, et al.
Nature Communications|February 25, 2023
Identification of SARS-CoV-2 M<sup>pro</sup> inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2Nobuyo Higashi-Kuwata, Kohei Tsuji, Hironori Hayashi, et al.
Pageof 7